Health economics of targeted cancer therapies: A comparative analysis for Serbia and the Netherlands

Mihajlovic, J. 2016 [Groningen]: Rijksuniversiteit Groningen. 175 p.

Research output: ScientificDoctoral Thesis

Copy link to clipboard


  • Title and contents

    Final publisher's version, 229 KB, PDF-document

  • Chapter 1

    Final publisher's version, 215 KB, PDF-document

  • Chapter 2

    Final publisher's version, 553 KB, PDF-document

  • Chapter 3

    Final publisher's version, 283 KB, PDF-document

  • Chapter 4

    Final publisher's version, 413 KB, PDF-document

  • Chapter 5

    Final publisher's version, 1 MB, PDF-document

    Embargo ends: 12/03/2018

  • Chapter 6

    Final publisher's version, 805 KB, PDF-document

    Embargo ends: 12/03/2018

  • Chapter 7

    Final publisher's version, 361 KB, PDF-document

  • Chapter 8

    Final publisher's version, 199 KB, PDF-document

  • Summary

    Final publisher's version, 74 KB, PDF-document

  • Samenvatting

    Final publisher's version, 98 KB, PDF-document

  • Bibliography

    Final publisher's version, 83 KB, PDF-document

  • Research Institute SHARE

    Final publisher's version, 173 KB, PDF-document

  • Acknowledgments

    Final publisher's version, 89 KB, PDF-document

  • Curriculum vitae

    Final publisher's version, 92 KB, PDF-document

  • Appendix

    Final publisher's version, 379 KB, PDF-document

  • Complete thesis

    Final publisher's version, 2 MB, PDF-document

    Embargo ends: 12/03/2018

  • Jovan Mihajlovic
Targeted cancer therapies (TCTs) present a breakthrough that marked the field of medical oncology over the last two decades. These therapeutics brought improvements in survival and/or quality of life for various metastatic cancers, which came at a considerable cost. This thesis is centred on contrasting TCTs’ costs and effectiveness in the conditions of Serbia. Additionally, inferences drawn for Serbia were tested through simultaneous analyses in Dutch setting whenever possible.
Firstly, the thesis examined the general conditions in epidemiology of cancer and access to the TCTs in Serbia. Furthermore, it dealt with the estimation of costs and effectiveness in an example of metastatic renal cell cancer TCTs within the Serbian and the Dutch setting. In that way major issues in modelling of TCTs effectiveness were illustrated. Costs minimisation analysis of same TCTs with different routes of administration served to describe the pattern of supportive costs in TCTs’ use within Serbian and Dutch practice.
Raising mortality and relatively poor survival with the disease stressed cancer as one of the main health issues in Serbia. Although broader access to TCTs is possible and may contribute to the improvement of cancer survival, most of TCTs would not appear cost effective under traditionally accepted thresholds. In order to enable effective TCTs evaluation, Serbia needs to constitute a rational reimbursement policy with clear definition and important role of pharmacoeconomics within it. Finally, relying on Dutch experiences TCTs may require even more elaborated reimbursement regulations with emphasis on appropriate cost effectiveness modelling.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date12-Sep-2016
Place of Publication[Groningen]
Print ISBNs978-90-367-9078-9
Electronic ISBNs978-90-367-9074-1
StatePublished - 2016

View graph of relations

Download statistics

No data available

ID: 35019538